Is SYRE or TCRX more undervalued in 2026?

CirclFi compares Spyre Therapeutics, Inc. (SYRE) and TScan Therapeutics, Inc. (TCRX) using 13 institutional-grade valuation models. SYRE has a Quality of Company score of 5.4/10 while TCRX scores 6.4/10.

Which is a better buy — SYRE or TCRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SYRE and TCRX valuations compare?

SYRE at $72.11 and TCRX at $1.08 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SYRE vs TCRX Valuation Comparison 2026 — Intrinsic Value Analysis

SYRE

Biotechnology

Spyre Therapeutics, Inc.

Quality

5.4

out of 10

Value Trap

SAFE

Price

$72.11

Last close

Models

12/13

Active

TCRX

Biotechnology

TScan Therapeutics, Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$1.08

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	SYRE Fair Value	SYRE Upside	TCRX Fair Value	TCRX Upside
Bayesian DCF	Intrinsic	$22.23	-69.2%	$0.71	-34.5%
Earnings Power Value	Intrinsic	$30.32	-56.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$2.02	-97.3%	$1.66	+53.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SYRE vs TCRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SYRE vs TCRX — Which Stock Is More Undervalued?

TCRX scores higher with a 6.4/10 quality rating vs SYRE's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Spyre Therapeutics, Inc. (SYRE) and TScan Therapeutics, Inc. (TCRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SYRE currently trades at $72.11 with a QOC of 5.4/10, while TCRX trades at $1.08 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).